If their First in Man (Phase I) results for their oral gram negative ID program shows good safety, it should go to phase 2B. That's why they raised $54 mil on July 16.
You are viewing a single comment's thread from:
If their First in Man (Phase I) results for their oral gram negative ID program shows good safety, it should go to phase 2B. That's why they raised $54 mil on July 16.
I could see their website and the timeline where they are advancing their products, I find interesting the line of extremely potent drugs. In our experience and due to the high cost of these drugs, we discovered that if we use drugs that we didn't use before because we thought they were obsolete they limit certain diseases, it is interesting how bacteria evolve in a linear way.